Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children

Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children

MIMOSA study aims to characterize from behavioral, neurophysiological and neurocognitive perspectives children and adolescents with attention deficit hyperactivity disorder (ADHD), in order to identify a possible biomarker of response to medication treatments. To achieve this aim, in the study children with ADHD (drug naive) are recruited and undergo behavioral and clinical screenings, neurocognitive profile, and neurophysiological evaluation with functional near infrared spectroscopy (fNIRS). ADHD group is evaluated before the beginning of medications, at first dose of medication (only imaging evaluation fNIRS), and after a period of two/three months of continuous treatment with medication.

Inclusion Criteria:

• diagnosis of ADHD according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) criteria;
• drug naive

Exclusion Criteria:

• presence of intellectual disability, neurological diseases, epilepsy, genetic syndromes
• and previous treatment with psychoactive drugs